Trends in GPCR drug discovery: new agents, targets and indications.
OA: closed
⤵ 3 in-corpus citations
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (3)
- GPR162 Drives Obesity-Associated Lung Adenocarcinoma Suppression via Fatty Acid Oxidation-Induced Cuproptosis and Metabolic-Immune Reprogramming 2026
- Pharmacological characterization and radiolabeling of VUF15485, a high-affinity small-molecule agonist for the atypical chemokine receptor ACKR3 2023
- Different conformations of EGF-induced receptor dimers involved in signaling and internalization 2022
Cited by (3)
- GPR162 Drives Obesity-Associated Lung Adenocarcinoma Suppression via Fatty Acid Oxidation-Induced Cuproptosis and Metabolic-Immune Reprogramming 2026
- Pharmacological characterization and radiolabeling of VUF15485, a high-affinity small-molecule agonist for the atypical chemokine receptor ACKR3 2023
- Different conformations of EGF-induced receptor dimers involved in signaling and internalization 2022
Source provenance
- europepmc
- last seen: 2026-06-28T06:08:18.748782+00:00